STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals

Telomir Pharmaceuticals Advances Groundbreaking Research in Copper-Binding Therapies for Wilson’s Disease

byLiliana Vida
December 23, 2024
in Pharmaceuticals, Small-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

Emerging Findings Position Telomir-1 as a Promising Solution for Copper Metabolism Disorders and Expand Its Potential Applications

Telomir Pharmaceuticals (TELO), a pioneering force in age-reversal science, has unveiled significant advancements in its research on Telomir-1, a compound demonstrating exceptional copper-binding capabilities. The findings pave the way for exploring Telomir-1 as a transformative treatment for Wilson’s disease, a rare and life-threatening genetic disorder.

Breakthrough in Copper Metabolism Research

Recent preclinical studies conducted by Recipharm and Smart Assays underscore Telomir-1’s superior binding affinity for copper ions, establishing its ability to regulate copper metabolism effectively. Moreover, the compound’s capacity to bind and exchange essential ions like copper, iron, and zinc highlights its unique therapeutic profile.

Dr. Itzchak Angel, Chief Scientific Advisor at Telomir, remarked, “These groundbreaking results showcase Telomir-1’s potential to address a critical unmet need in Wilson’s disease by targeting the underlying causes rather than merely managing symptoms.”

Wilson’s Disease: An Unmet Medical Challenge

Affecting approximately 1 in 30,000 individuals globally, Wilson’s disease stems from mutations in the ATP7B gene, which disrupts copper regulation. This results in toxic copper accumulation in vital organs, including the liver and brain, leading to severe complications such as liver failure, neurological damage, and psychiatric disorders.

Current treatments, including chelating agents and zinc therapy, are fraught with drawbacks. Chelating agents may cause side effects like kidney damage and gastrointestinal issues, while zinc therapy can lead to anemia and diminished effectiveness over time. Telomir-1 offers a potentially safer and more targeted alternative, addressing the disease’s root cause with fewer adverse effects.

The orphan drug designation opportunity for Wilson’s disease could expedite Telomir-1’s development, offering regulatory and financial incentives.

Expanded Research Horizons

Building on Telomir-1’s copper-binding potential, Telomir Pharmaceuticals is diversifying its research pipeline to explore various therapeutic areas:

  1. Type 2 Diabetes: Preclinical models indicate Telomir-1’s potential to reverse metabolic imbalances associated with diabetes.
  2. Progeria and Aging: Telomir-1’s effects on telomere function and accelerated aging are under investigation.
  3. Cancer Research: The compound’s anti-cancer potential is being examined through xenograft studies.
  4. Alzheimer’s Disease: Early studies suggest Telomir-1 could mitigate cognitive decline linked to neurodegeneration.
  5. Metal Toxicity: The drug aims to restore cellular balance by regulating harmful metal levels.
  6. DNA Methylation: Telomir-1’s role in addressing epigenetic changes that contribute to aging and chronic diseases is being explored.

From Veterinary Research to Human Applications

Earlier this year, Telomir discontinued a veterinary osteoarthritis study due to ethical concerns regarding induced conditions in animals. Instead, the company plans a new study with naturally affected elderly dogs. This decision aligns with Telomir’s commitment to ethical research while advancing its dual application strategy for both human and veterinary medicine.

Future Milestones and Market Outlook

Telomir Pharmaceuticals is advancing its manufacturing processes to produce GMP-grade Telomir-1 for IND-enabling safety studies, targeting clinical trials by 2026. With the global anti-aging drugs market projected to grow from $91.05 billion in 2024 to $160.24 billion by 2031, Telomir-1’s novel approach positions the company to capitalize on a rapidly expanding sector.

By addressing the root causes of age-related diseases, Telomir aims to redefine patient care and extend health span, offering transformative solutions for a growing aging population.

Leadership Commitment

Erez Aminov, Chairman and CEO, emphasized, “Telomir remains dedicated to advancing Telomir-1’s development while creating value for our shareholders. The recent financing at a 20% premium without warrants underscores investor confidence in our vision.”

Conclusion

Telomir Pharmaceuticals’ strides in copper-binding research signal a paradigm shift in treating Wilson’s disease and other copper-related disorders. As the company deepens its research and prepares for clinical milestones, Telomir-1’s potential to revolutionize treatment approaches for age-related and chronic conditions becomes increasingly apparent.

By leveraging innovative science and maintaining a patient-centered ethos, Telomir Pharmaceuticals is on the cusp of redefining therapeutic possibilities in modern medicine.

Read original press release here

You might like this article:Why My Size (NASDAQ: MYSZ) and Taoping Inc. (NASDAQ: TAOP) Shares Are Soaring

Tags: GrowthMoversNewsStock MarketTELOTelomir PharmaceuticalsWilson's Disease
Previous Post

Why My Size (NASDAQ: MYSZ) and Taoping Inc. (NASDAQ: TAOP) Shares Are Soaring

Next Post

MicroStrategy Reports $561M Share Sale and Expands Bitcoin Holdings

Related Posts

scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

byLuca Blaumann
August 19, 2025
0

Strong weight reduction overshadowed by concerns over side effects Viking Therapeutics (VKTX) shares plummeted nearly 45% on Tuesday after the...

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

byLuca Blaumann
August 14, 2025
0

Frontier technology firm posts strong top-line growth, boosts BTC portfolio, and advances R&D in energy systems and robotics KULR Technology...

chemistry-2

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

byLuca Blaumann
August 14, 2025
0

Partnership leverages artificial intelligence to accelerate discovery of next-generation treatments for obesity and cardiometabolic diseases Eli Lilly (LLY) has entered...

Next Post
bitcoin-1

MicroStrategy Reports $561M Share Sale and Expands Bitcoin Holdings

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

Intel Shares Surge After $2 Billion SoftBank Investment

Strategy Expands Bitcoin Holdings With $51 Million Purchase

Based on Your Interest

Aerospace & Defense

Amphenol Expands Defense Portfolio With $1 Billion Trexon Acquisition

August 18, 2025
investing
Insurance

Buffett Bet Sends UnitedHealth Shares Soaring

August 18, 2025
Small-Cap

KULR Technology Group Reports Record Q2 Revenue and Expands Bitcoin Treasury Holdings

August 14, 2025

Recommended

Financial Services

Berkshire Hathaway Adds New Stakes Across Healthcare, Industrials, and Real Estate

August 14, 2025
Pharmaceuticals

Eli Lilly Strikes $1.3 Billion Deal with Superluminal Medicines to Advance AI-Driven Obesity Drug Development

August 14, 2025
Large-Cap

Ulta and Target to End Mini-Store Partnership in 2026

August 14, 2025
Airlines

Spirit Aviation Warns of Possible Collapse as Cash Runs Low

August 13, 2025
Large-Cap

Cava Shares Plunge as Chain Cuts Same-Store Sales Outlook

August 12, 2025
Stoxpo

Follow us on social media:

Highlights

  • Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual
  • Intel Seeks More Equity Infusions Amid Mounting Financial Strains
  • Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial
  • Intel Shares Surge After $2 Billion SoftBank Investment
  • Strategy Expands Bitcoin Holdings With $51 Million Purchase

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Casual Dining’s Comeback: Why Sit-Down Chains Are Beating Fast Casual

August 21, 2025

Intel Seeks More Equity Infusions Amid Mounting Financial Strains

August 20, 2025
scientist

Viking Therapeutics Shares Plunge After High Dropout Rate in Weight-Loss Pill Trial

August 19, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?